share_log

Prime Medicine, Inc.'s Quiet Period Set To Expire on November 29th (NYSEARCA:PRME)

Prime Medicine, Inc.'s Quiet Period Set To Expire on November 29th (NYSEARCA:PRME)

Prime Medicine, Inc.s 的静默期定于 11 月 29 日到期 (NYSEARCA: PRME)
Financial News Live ·  2022/11/30 09:53

Prime Medicine's (NYSEARCA:PRME – Get Rating) quiet period will end on Tuesday, November 29th. Prime Medicine had issued 10,294,118 shares in its public offering on October 20th. The total size of the offering was $175,000,006 based on an initial share price of $17.00. During the company's quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Prime Medicine（NYSEARCA: PRME — Get Rating）的静默期将于11月29日星期二结束。Prime Medicine在10月20日的公开发行中发行了10,294,118股股票。根据17.00美元的初始股价，此次发行的总规模为17.5,000,006美元。在公司的平静时期，由于美国证券交易委员会的规定，参与首次公开募股的内部人士和承销商无法发布该公司的任何收益预测或研究报告。在该公司的平静期结束后，预计担任该股承销商的经纪商将开始对该公司的研究报道。

Analyst Ratings Changes

分析师评级变化

Several research analysts have recently commented on the company. Morgan Stanley assumed coverage on Prime Medicine in a research report on Monday, November 14th. They issued an "equal weight" rating and a $23.00 target price for the company. JPMorgan Chase & Co. started coverage on shares of Prime Medicine in a report on Monday, November 14th. They set an "overweight" rating and a $27.00 target price on the stock. Jefferies Financial Group assumed coverage on shares of Prime Medicine in a report on Monday, November 14th. They issued a "buy" rating and a $25.00 price target for the company. Finally, The Goldman Sachs Group assumed coverage on shares of Prime Medicine in a research note on Monday, November 14th. They set a "neutral" rating and a $22.00 price objective on the stock.

几位研究分析师最近对该公司发表了评论。摩根士丹利在11月14日星期一的一份研究报告中假设对Prime Medicine进行了报道。他们为该公司发布了 “同等权重” 评级和23.00美元的目标价格。摩根大通在11月14日星期一的一份报告中开始报道Prime Medicine的股票。他们为该股设定了 “增持” 评级和27.00美元的目标价格。杰富瑞金融集团在11月14日星期一的一份报告中假设对Prime Medicine的股票进行了报道。他们为该公司发布了 “买入” 评级和25.00美元的目标价。最后，高盛集团在11月14日星期一的一份研究报告中假设对Prime Medicine的股票进行了报道。他们对该股设定了 “中性” 评级和22.00美元的价格目标。

Get
获取
Prime Medicine
主要医学
alerts:
警报：

Prime Medicine Price Performance

优质药物价格表现

Shares of NYSEARCA:PRME traded down $0.11 on Tuesday, reaching $17.33. 227,386 shares of the company traded hands, compared to its average volume of 340,970. Prime Medicine has a fifty-two week low of $14.52 and a fifty-two week high of $21.73. The company's 50 day moving average is $19.34 and its 200-day moving average is $19.91.

NYSEARCA: PRME的股价周二下跌0.11美元，至17.33美元。该公司的股票交易量为227,386股，而平均交易量为340,970股。Prime Medicine创下五十二周低点14.52美元，五十二周高点为21.73美元。该公司的50天移动平均线为19.34美元，其200天移动平均线为19.91美元。

Insider Buying and Selling at Prime Medicine

Prime Medicine 的内幕买入和

In other news, Director Thomas Cahill purchased 400,000 shares of the company's stock in a transaction dated Monday, October 24th. The shares were bought at an average price of $17.00 per share, with a total value of $6,800,000.00. Following the completion of the transaction, the director now directly owns 5,305,679 shares in the company, valued at approximately $90,196,543. The purchase was disclosed in a filing with the SEC, which is available through
在其他新闻方面，董事托马斯·卡希尔在10月24日星期一的一笔交易中购买了该公司40万股股票。这些股票的平均价格为每股17.00美元，总价值为6,800,000.00美元。交易完成后，董事现在直接拥有该公司的5,305,679股股份，价值约为90,196,543美元。此次收购是在向美国证券交易委员会提交的文件中披露的，该文件可通过以下方式获得
this link
这个链接
. In other Prime Medicine news, major shareholder 2019 Gp L.L.C. Gv acquired 800,000 shares of Prime Medicine stock in a transaction dated Monday, October 24th. The stock was bought at an average cost of $17.00 per share, with a total value of $13,600,000.00. Following the completion of the transaction, the insider now owns 11,522,248 shares of the company's stock, valued at $195,878,216. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through
。在Prime Medicine的其他新闻中，主要股东2019年Gp L.C.Gv在10月24日星期一的一笔交易中收购了80万股Prime Medicine股票。该股票的平均买入成本为每股17.00美元，总价值为13,600,000.00美元。交易完成后，知情人现在拥有该公司11,522,248股股票，价值195,878,216美元。此次收购是在向美国证券交易委员会提交的文件中披露的，该文件可通过以下方式获得
the SEC website
美国证券交易委员会网站
. Also, Director Thomas Cahill acquired 400,000 shares of Prime Medicine stock in a transaction dated Monday, October 24th. The stock was acquired at an average cost of $17.00 per share, with a total value of $6,800,000.00. Following the completion of the transaction, the director now directly owns 5,305,679 shares of the company's stock, valued at approximately $90,196,543. The disclosure for this purchase can be found
。此外，董事托马斯·卡希尔在10月24日星期一的一笔交易中收购了40万股Prime Medicine股票。该股票的收购平均成本为每股17.00美元，总价值为6,800,000.00美元。交易完成后，董事现在直接拥有该公司5,305,679股股票，价值约为90,196,543美元。可以找到此次收购的披露信息
here
这里
.
。

About Prime Medicine

关于普瑞米医学

(Get Rating)

（获取评分）

Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.

Prime Medicine, Inc是一家生物技术公司，通过部署基因编辑技术提供基因疗法来治疗疾病。它为 Prime Editor 提供 Prime Editor 蛋白，包括 Cas 蛋白和逆转录酶之间的融合；以及一个 pegRNA，它将 Prime Editor 靶向特定的基因组位置，为对目标 DNA 序列进行所需编辑提供了模板。

Read More

阅读更多

  • Get a free copy of the StockNews.com research report on Prime Medicine (PRME)
  • Three Reasons It's Time To Get Bullish On Organigram
  • Opportunity Strikes! Hibbett, Inc Falls Flat On Strong Results
  • Why Investors Are Eating Up Restaurant Brands International
  • Zoom Video Continues to Work Through Normalization
  • What an Inverted Yield Curve Means for Investors
  • 免费获取 StockNews.com 关于 Prime Medicine (PRME) 的研究报告
  • 是时候看好 Organigram 的三个原因了
  • 机会来袭！Hibbett, Inc. 因业绩强劲而持平
  • 为什么投资者正在吞噬国际餐厅品牌
  • Zoom 视频通过标准化继续发挥作用
  • 收益率曲线倒置对投资者意味着什么

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.

接收《主要医学日报》的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Prime Medicine及相关公司的最新新闻和分析师评级的简明每日摘要。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发